Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAIR-HF2 trial of intravenous ferric carboxymaltose in systolic heart failure with iron deficiency
2016-000068-40Phase 4Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in heart failure with reduced ejection fraction (HFrEF) and iron deficiency anemia (IDA) comparing Ferric carboxymaltose with Placebo (2 arms). Started Sep 2016; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with reduced ejection fraction (HFrEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2016-000068-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000068-40.